Pyridine Carbamates Modulating GluN2B Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders lack effective modulators for GluN2B-containing NMDA receptors, which are implicated in various conditions including depression, Alzheimer's disease, and pain, highlighting the need for compounds that can specifically target and modulate these receptors.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, isotopic variants, and N-oxides, which can modulate GluN2B receptor activity, offering potential therapeutic benefits for a range of disorders mediated by GluN2B receptor function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurological and psychiatric disorders, then existing therapeutic options are available, but effective modulators for GluN2B-containing NMDA receptors are lacking
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that target the GluN2B receptor subunit specifically. The compounds contain particular functional groups and structural features that confer selectivity for GluN2B over other NMDA receptor subunits, enabling localized and specific modulation of this receptor subtype to treat neurological and psychiatric disorders
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the compounds (such as substituents R1-R6, ring structures, and functional groups in Formula I) to optimize binding affinity and selectivity for GluN2B receptors. By adjusting these chemical parameters, the invention achieves effective modulation of GluN2B-containing NMDA receptors while maintaining selectivity
2Reliability
If compounds of Formula (I) are developed to modulate GluN2B receptor activity, then therapeutic benefits for disorders such as depression, Alzheimer's disease, and pain can be achieved, but the complexity of identifying and developing specific GluN2B modulators increases
Solution Approach 1:
The patent applies segmentation by dividing the complex task of developing GluN2B modulators into systematic steps: identifying core structural frameworks (Formula I), defining specific substituent patterns (R1-R6 groups), and progressively optimizing individual molecular components. This segmented approach to drug discovery reduces the overall complexity by breaking down the development process into manageable stages with clear design criteria
Data Source
AI summary
Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.